<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.pharmexec.com/view/white-house-withdraws-dr-heidi-overton-nomination-fda-commissioner-report</loc>
      <lastmod>2026-11-18T15:28:24.565Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:28:24.565Z</news:publication_date>
        <news:title><![CDATA[White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/pfizer-verismo-licensing-deals-car-t-manufacturing-in-vivo</loc>
      <lastmod>2026-11-18T14:41:34.832Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:41:34.832Z</news:publication_date>
        <news:title><![CDATA[Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/workload-balance-between-humans-agentic-models</loc>
      <lastmod>2026-11-18T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T11:00:00Z</news:publication_date>
        <news:title><![CDATA[The Workload Balance in Pharma Between Humans and Agentic Models]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/-daily-fda-approves-cosentyx-wilserdly</loc>
      <lastmod>2026-11-17T20:12:31.812Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:12:31.812Z</news:publication_date>
        <news:title><![CDATA[Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/gilead-signs-royalty-free-licensing-deals-broaden-access-obeldesivir</loc>
      <lastmod>2026-11-17T14:56:51.962Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:56:51.962Z</news:publication_date>
        <news:title><![CDATA[Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/fda-approves-cosentyx-polymyalgia-rheumatica-wilserdly-er-positive-esr1-mutated-advanced-breast-cancer</loc>
      <lastmod>2026-11-17T14:27:53.162Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:27:53.162Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Cosentyx for Polymyalgia Rheumatica, Wilserdly for ER-Positive ESR1-Mutated Advanced Breast Cancer ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/workflows-impacted-agentic-models-beyond-productivity-gains</loc>
      <lastmod>2026-11-17T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T11:00:00Z</news:publication_date>
        <news:title><![CDATA[How Pharma Workflows Are Impacted by Agentic Models Beyond Productivity Gains]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/daily-fda-approves-three-new-therapies</loc>
      <lastmod>2026-11-16T20:07:51.114Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:07:51.114Z</news:publication_date>
        <news:title><![CDATA[Pharmaceutical Executive Daily: FDA Approves Three New Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/johnson-acquires-ollin-biosciences-eli-lilly-calytrix-bio-amyriad-therpaeutics-ad04-alzheimers-sanofi-collaboration-seawolf-therapeutics</loc>
      <lastmod>2026-11-16T17:49:59.462Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:49:59.462Z</news:publication_date>
        <news:title><![CDATA[M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmexec.com/view/fda-approves-klygefa-gazyva--igalm</loc>
      <lastmod>2026-11-16T16:56:06.974Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>PharmExec</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:56:06.974Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia ]]></news:title>
      </news:news>
	</url></urlset>